Newsroom - Argenx
Nov 5, 2024 · This quarter we: ️ Increased our patient impact, expanding our gMG footprint and delivering innovation to CIDP patients. ️ Advanced Vision 2030, investing in our continuous pipeline of differentiated antibody candidates, with the goal of reaching 50,000 patients and 10 labeled indications by 2030.
Press Releases - Argenx
Nov 5, 2024 · argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy. August 28, 2024. argenx to Present at Upcoming Investor Conferences. July 25, 2024. argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update.
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic ...
Jun 21, 2024 · argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with chronic ...
argenx | Homepage - Reaching Patients Through Immunology …
At argenx, we’ve created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease pathways and differentiated therapeutic antibodies.
argenx | argenx to Report Third Quarter 2024 Financial Results and ...
Oct 31, 2024 · argenx Reports Third Quarter 2024 Financial Results and Provides Business Update. Amsterdam, the Netherlands. $573 million in third quarter global net product sales. CIDP global expansion on track, with decisions on approval under review in …
argenx | argenx Announces U.S. Food and Drug Administration …
Dec 17, 2021 · VYVGART is the first-and-only FDA-approved neonatal Fc receptor blocker. 68% of anti-acetylcholine receptor (AChR) antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis - Activities of Daily Living (MG-ADL) scale compared with 30% of patients treated with placebo (n=19/64) (p<0.0001) during the ...
argenx | argenx Reports Topline Results from ADVANCE-SC Study …
Nov 28, 2023 · argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced topline results from the ADVANCE-SC study evaluating VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with primary immune thrombocytopenia (ITP). The study did ...
argenx | argenx Data Highlight Evidence that VYVGART and …
Apr 16, 2024 · argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that data from its Phase 3 ADHERE trial evaluating VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in patients with chronic inflammatory demyelinating polyneuropathy ...
argenx raises $1.1 billion in gross proceeds in a global offering
Jul 18, 2023 · argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced today the pricing of a global offering of ordinary shares, which may be represented by American Depository Shares (“ADSs”).
argenx Reports Full Year 2023 Financial Results and ...
Feb 28, 2024 · argenx continues to demonstrate breadth and depth within its immunology pipeline and is advancing multiple pipeline-in-a-product candidates. With efgartigimod, argenx is solidifying its leadership in FcRn and is on track to be approved or in development in 15 autoimmune indications by 2025.